Tumor markers are usually defined as molecules produced by malignancies, whose presence or altered serum concentration, as compared with normal values, gives an indication that a tumor exists. Carcinoembryonic antigen (CEA) is a widely used human tumor marker for a variety of carcinomas (reviewed in Shively and Beatty, 1985) . It is a membrane-bound glycoprotein that is also released into the blood and other body fluids. For this reason, not only are post-operative CEA serum levels a useful parameter for monitoring recurrent tumors, but the presence of CEA on the surface of tumor cells also offers the possibility of localizing tumors with CEA-specific, radiolabelled antibodies and targetting in immunotherapy. CEA is not a tumor-specific antigen, but it has only a low steady-state concentration in normal tissues.
CEA is a member of a family of glycoproteins with variable expression patterns. CEA-related antigens are present in different normal tissues: for example, non-specific crossreacting antigen (NCA) is found in granulocytes, while biliary glycoprotein (BGP) is present in bile (reviewed in Thompson et al., 1991) . The protein backbone, as determined by protein microsequencing or as derived through molecular cloning, reveals high sequence similarity among individual members of the CEA family. A gene family exists, comprising at least 22 genes (Khan et al., 1992) closely clustered on the long arm of chromosome 19 . Sequence comparisons allow a division into 2 main sub-groups, one encoding the classical CEA and cross-reacting antigens, the other the pregnancy-specific glycoproteins (PSGs) expressed in increasing amounts by the placenta during pregnancy.
A major problem in studying the expression of CEA-related antigens at the protein level has been the lack of wellcharacterized antibodies that are specific for individual antigen species. Through molecular cloning and the creation of stable transfectants expressing individual members of the CEA family, panels of monoclonal antibodies (MAbs) have been tested using FACscan analyses to better define their specificities (Daniel et al., 1993) . The mass of sequence data produced in the last few years has also made it possible to study the expression patterns of individual members at mRNA level. Transcripts have been found by cDNA cloning studies and DNA/RNA hybridization (Northern) analyses for 17 CEArelated genes (reviewed in Khan et al., 1992) , yet the assignment of each CEA-related antigen to a specific gene remains difficult. Nevertheless, transcripts have been assigned to CEA (Oikawa et al., 1987) , NCA-50/90 , NCA-95 (Berling ef al., 1990) and BGP .
Although the CEA cross-reacting antigens are expressed in various normal tissues, they may also be useful as tumor markers. For example, PSGs have been used as markers for choriocarcinomas (Sakuragi, 1982) . A 3.9-kb transcript for BGP has been reported not only in normal human hepatocytes but also in 16/21 hepatocellular carcinomas (Hinoda et al., 1990) . NCA but not CEA transcripts are more prevalent in benign adenomas and colonic carcinomas than in adjacent normal mucosa, indicating the potential use of NCA as a marker for progression towards malignancy of colonic tumors (Chi et al., 1991) . In contrast, CEA and BGP transcripts have recently been reported to be more prevalent in certain lung tumors than in corresponding normal tissues (Kim et al., 1992) . We here examine in more detail the potential usefulness of individual members of the CEA family as tumor markers and attempt to determine their expression patterns more exactly.
It is usually necessary to use labelled DNA fragments to visualize transcripts using the DNA/RNA hybridization method. However, due to their high sequence similarities, it is not possible to differentiate all CEA-related transcripts with DNA fragment probes. On the basis of existing sequence data, we describe here the design and testing of oligonucleotide primer pairs to identify specific CEA-related transcripts in human tumors, using the reverse transcriptase/polymerase chain reaction (RT/PCR). The presence or absence of given transcripts has been correlated with the presence or absence of corresponding antigens as indicated by MAbs specific for CEA, NCA-50/90 and NCA-95.
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MATERIAL AND METHODS

Oligonucleotide primers
Sequence comparisons of individual CEA-gene-family members were carried out using published sequences to design oligonucleotides specific for CEA, NCA, BGP, CGM6, CGM1, CGM7 and for PSG1-PSG15 (Table I) . A set of oligonucleotide primers was also synthesized for amplification of all known CEA-gene-family members. In order to achieve this, the program "Primer" was applied (Lucas et al., 1991) . This program was developed in our group for the comparison and identification of specific nucleotide sequences from gene families.
Source of cDNA clones
A full-length CEA cDNA clone was constructed (Pdegrin et al., 1992), sub-cloned into a Bluescript M13+KS vector (Stratagene, La Jolla, CA) and linearized prior to PCR analysis by Hind111 digestion. A 2-kb EcoRI fragment of the cDNA clone pNCAl containing the coding region of NCA and a BamHI/EcoRI fragment from the partial BGP cDNA clone 18 (Hinoda et al., 198S) , both kindly made available by Dr. J. Shively (Beckman Research Institute, Duarte, CA) were also used for primer specificity testing. For CGM6, a full-length cDNA clone in the Bluescript vector (Berling et al., 1990) was linearized using EcoRI, as was the PSG3 cDNA clone pSP-li (Rooney et al., 1988) , which was a kind gift from Dr. N. Hardman (Ciba-Geigy, Basel, Switzerland). A CGM7 cDNA clone which was provided by Dr. M. Kuroki (Fukuoka, Japan) and a cDNA clone containing the complete coding region of CGMla (Nagel et al., 1993) were also used for primer testing. Tumor source, RNA extraction and polymerase-chain-reaction conditions
The tumors located in the brain and relevant clinical data were kindly provided by Dr. Seeger (Department of Neurosurgery, University Hospital, Freiburg, Germany). The gynecological tumors and clinical data were from Dr. T. Bauknecht (Department of Gynecology, University Hospital, Freiburg, Germany) and Dr. J. Arsenau (Department of Pathology, Royal Victoria Hospital, Montreal, Canada). Tumor material was quick-frozen in liquid nitrogen and stored at -70°C prior to RNA isolation from 0.5 to 1 g tumor tissue, using the acid phenol extraction method described by Chomczynski and Sacchi (1987) or the guanidinium-isothiocyanate extraction procedure (Sambrook et al., 1989) . Tissues were first ground under liquid nitrogen with a pestle and mortar and finely homogenized in extraction buffer using a tight-fitting glass/ Teflon homogenizer.
Reverse transcription and polymerase chain reactions were slightly modified after Sambrook et al. (1989) , as described in Lucas et al. (1991) . For the reverse transcription step, either 25 pmole of the selected 3' oligonucleotide or later 50 pmole of a random hexamer mixture (Pharmacia, Uppsala, Sweden) were used to prime first-strand DNA synthesis from 200 ng or 1 pg of total RNA. The optimized system utilized 50 pmole of random hexamer and 1 pg of total RNA for reverse transcription. The specific oligonucleotides (50 pmole each) were added after the reverse-transcription step, and 30 amplification cycles were applied using optimal annealing temperatures (Table I) for the given primer sets (15 sec/step).
Prior to testing for the presence of CEA-related transcripts, the integrity of the RNA extracted from various tumors was determined. This control was to rule out false negative results where the RNA may be degraded, or reverse transcription and/or DNA amplification inhibited due to the presence of impurities. It was achieved by PCR using a primer set to amplify p-actin transcripts. This was tested both with and without reverse transcriptase, so as to avoid false positive signals due to contaminating DNA in the preparations. It is known that a large number of processed p-actin pseudogenes exists (Ng et al., 1985) , and, in the absence of the reverse transcription step, positive signals of the same size as from the mRNA reveal DNA contamination. However, even in the presence of contamination, differences in signal strength or banding pattern can still be used to confirm RNA integrity. As no intronless pseudogenes have so far been discovered for the CEA-gene family, DNA contamination should not create problems with the PCR. In the search for another ubiquitously PCRABL3' 5'-GTGATGTAGTTGCITGGGAC-3' internal 388 -407
Fainstein et a/., c-abl expressed control mRNA, where no processed pseudogenes exist, we synthesized a primer set (Table I) for the amplification of the Ib transcripts for the proto-oncogene c-abl (Bernards et al., 1987) .
For each primer set, positive and negative controls were included in the RT/PCR reaction. As a negative control, water instead of RNA was used in all cases. For the CEAall, CEA and NCA sets, we initially used RNA from a human colonic tumor and later from an ovarian mucinous tumor as positive controls. Total RNA from leukocytes of a chronic myeloid leukemia patient and later RNA from transfectants expressing the respective CEA-family members were the positive controls for the BGP, CGM1, CGM6 and CGM7 primer sets. Alternatively, for the BGP set, RNA from the human adenocarcinoma cell line HT29 was also used. The positive control for the PSGall primer set was total RNA from a term placenta.
Transfer of DNA and oligonucleotide hybridization After size separation of DNA fragments on agarose gels, alkaline transfer to Biodyne B membranes (PALL, Dreieich, Germany) was carried out according to Chomczynski and Qasba (1984) . The following oligonucleotides were synthesized as specific internal probes to unequivocally identify each amplification product: The sequence source for each oligonucleotide is as listed in Table I . The minima1 number of mismatches to other members of the CEA gene family are indicated in brackets. The CEA/PSGall oligonucleotide was designed to hybridize with all family members with maximally 1 mismatch. For the PSGall-specific probe, maximally 2 mismatches were found to all PSG sub-group members. Oligonucleotides were 5'-endlabelled, hybridized (Sambrook et al., 1989) and washed to approximately 4°C below their theoretical melting temperatures, as calculated according to Lathe (1985) , in 6x SSPE (1 x SSPE is 0.18 M NaCl, 10 mM Na-phosphate, pH 7.4, and 1 mM EDTA), 0.1% SDS. The maximal wash temperatures for the CEAIPSGall-and PSGall-specific oligonucleotides took into account a maximum of 1 or 2 mismatches respectively.
Immunohistochemistry
Frozen tumor material was embedded in Tissue Tek Freeze medium (Reichert-Jung, Vienna, Austria) and sectioned on a cryomicrotome (Model 2700 Frigocut, Reichert-Jung). Sections of 7 to 10 pm were stored on poly (L-lysine) coated slides at -7O"C, and parallel sections were stained with hemalaud eosin for identification of tissue structure. Prior to freezing, the sections were dried under vacuum at room temperature or 30°C for 1 to 2 hr and fixed for 10 min in acetone. Thawed sections were air-dried and re-hydrated in PBS. Endogenous peroxidase activity was blocked by incubation in 0.3% HzOz in methanol for 30 min. Pre-incubation with 3% ovalbumin, Grade I1 (Sigma, St. Louis, MO) was carried out before the antibody incubations were made. Monoclonal antibodies (Daniel et al., 1993) were used to differentiate CEA (26/3/13), NCA-50/90 (9A6FR) and NCA-95 (80H3) using the avidinbiotin (ABC) procedure and a Vectastain kit (Vector, Burlingame, CA). The first antibodies were diluted to a concentration of 5 pg/ml PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HP04, 1.8 mM KH2P04, pH 7.4) for incubation. The rabbit anti-mouse IgG bridge antibodies were used at a dilution of 15 pg/mI PBS and the avidin-biotin complex was diluted 1:125 in PBS. Counterstaining was carried out with hemalaun. Positive controls for CEA and NCA-50/90 were colonic tumor, or normal colon sections. For NCA-95, the positive control was a human blood smear. As negative control, the first antibody was either omitted from the buffer or replaced by mouse IgG. The specificity of the antibodies has been tested elsewhere in FACscan analyses, using stable transfectants expressing CEA, NCA-50/90, CGM6 (NCA-95), BGP, CGMl and CGM7 (Daniel et al., 1993) .
RESULTS
Development of a PCR system for identification of transcripts derived from CEA-gene-family members
In order to synthesize specific or common oligonucleotide primer sets it was necessary to compare all known CEA-genefamily DNA sequences. To be certain that the amplification products originated from tumor RNA and not from contaminating genomic DNA, the 5' and 3' oligonucleotides were chosen from different exons ( Table I) . The different primer sets were then tested and their annealing temperatures optimized for their specificities against various CEA-related cDNAs (Fig. 1) . One primer set (PCRCEAall5'/PCRCEAall3') was designed to amplify mRNA of all CEA-gene-family members and an amplification product of the expected size was found for all cDNA clones tested (Fig.  la) . In all cases, amplification fragments of the expected sizes were seen (Table I) . Despite theoretical specificity of the primer sets designed to amplify only individual members of the CEA-gene family, when tested against all cDNA clones, some cross-amplification with products of the same or different sizes was found Fig. 1, c; p. However, higher specificity was achieved by transferring the amplification products to nylon membranes and by hybridization with internal oligonucleotides specific for each product with their respective cDNA templates.
The c-abl primer set as a control for the integrity of the RNA was tested against total genomic DNA where no amplification signals were seen (data not shown) and optimized for amplification of total RNA extracts. In order to get visible signals for the c-abl transcript, 1 pg of total RNA per PCR was needed. For determination of the optimal amounts of total RNA needed to give visible signals in the PCR reaction for CEArelated transcripts, variable amounts of RNA from a human colon adenocarcinoma were tested. Although signals were still visible with 1 to 10 ng RNA for CEA and NCA, we used 200 ng total RNA for the first screenings. However, after comparing the results gained with the immunohistochemical staining patterns from the same tumors, it became obvious that the latter showed greater sensitivity. For this reason, and for uniformity with the c-abl control, we then increased the amount of total RNA to 1 pg/reaction.
Once the PCR conditions had been optimized, total RNA from selected tumors expected to be either positive (various carcinomas) or negative (different brain tumors), was tested for the presence of CEA-related transcripts (Table 11 ). In order to avoid screening each RNA with all primer sets, after determining the integrity of the RNA, a primer set was used which should amplify all CEA-related transcripts (Fig. la) . Those RNAs that were negative with this primer set were not further tested with specific oligonucleotides. Three carcinomas revealed expression products of the expected size for CEA and NCA: a squamous carcinoma of the lung, an adenocarcinoma of the pancreas (these were included as positive controls) and an adenocarcinoma located in the nasal sinuses. No transcripts were found for BGP, CGM6 or the PSG sub-group. CGMl and CGM7 transcripts were not determined. As expected, none of the neuroepithelial (n = 4) or the mesenchymal brain tumors FIGURE 1 -Specificity control of primer sets designed to amplify transcripts from individual CEA-gene-family members. PCR amplification was carried out using cDNA clones as templates from individual members of the CEA-gene family (listed above). A HincII digest of bacteriophage +X174T was used as a size marker. The following oligonucleotide primer sets (listed in Table I) were used: a, PCRCEAall; b, PCRCEA, c, PCRNCA, d, PCRBGP; e, PCRCGM6; f, PCRCGM1; g, PCRCGM7; h, PCRPSGall. Ethidium-bromide staining of the DNA after separation on a 1.8% agarose gel is shown in the upper section and the hybridization results in the lower section of each sub-figure, using the following 5'-end-labeled, internal oligonucleotides: u, CEA/PSGall; b, CEA-specific; c, NCA-specific; d , BGP-specific; e, CGM6-specific;f, CGM1-specific; g, CGM7-specific; h, PSGall-specific.
(n = 6) tested contained transcripts for any CEA-gene-family member (Table 11) .
Identijication of CEA-related transcripts in gynecological tumors
A larger-scale RT/PCR-screening was carried out on 63 different gynecological tumors ( Fig. 2; Table 111 ). The integrity of the RNA was first tested using the p-actin primer set, with and without the reverse transcription step. In some cases, DNA contamination revealed amplification products with and without reverse transcription (Fig. 2d: colon-tumor metastasis). However, the larger fragment representing the active p-actin gene with intervening intron sequences was visible only in the absence of reverse transcription. As this fragment usually disappeared after inclusion of reverse transcription, intact R N A must also be present in such R N A samples. Parallel controls with the c-abl primer set confirmed these results (data not shown). In cases where the R N A was intact, the expression of CEA and CEA-related transcripts was Ovarian carcinoma investigated. As seen in Table 111 , co-expression of CEA, NCA and occasionally BGP transcripts, but of no other CEA-genefamily member, was found in the mucinous ovarian carcinomas (n = lo), whereas CEA-related transcripts were found only in 4112 serous, 417 endometrioid and 217 clear-cell ovarian carcinomas. From 200 ng total RNA, benign leiomyomas of the uterus revealed no CEA-related transcripts (n = 7), whereas some endometrial adenocarcinomas as well as carcinomas of the cervix expressed transcripts for CEA (2/6), NCA (2/6) and BGP (2/6). For unequivocal identification of the different amplification products, the fragments were transferred to nylon membrane and hybridized at high stringency with transcript-specific oligonucleotides (Fig. 2a-c) . Although the lower hybridization signal seen in Figure 2c corresponds in size with the cross-amplification product seen with this BGP primer set in the ethidium-bromide-stained gel using the PSG3 cDNA as a control (Fig. Id) , it does not represent a PSG, since the same tumours as shown in Figure 2c were negative when tested with the PSGall primer set (data not shown). None of the tumors examined revealed the presence of transcripts for CGM1, CGM6, CGM7 or any PSG-sub-family member in the conditions used (data not shown).
Expression of CEA, NCA-50I90 and NCA-95 in gynecological tumors using spec@ MAbs
Apart from the internal positive and negative controls, the efficacy of the PCR system was tested at the antigen level using specific MAbs in standard immunohistochemical studies to differentiate CEA (Mab 26/3/13), NCA-50/90 (Mab 9A6FR) and NCA-95 (Mab 80H3). A typical staining pattern of these 3 Mabs is shown on serial sections of an ovarian mucinous carcinoma in Figure 3 . The CEA- (Fig. 3a) and NCA50-90- (Fig. 3b) specific antibodies both reveal positive staining of tumor cells, whereas NCA-95 is present only in granulocytes (Fig. 3c) and not in tumor cells in this example. The negative control reveals no unspecific background staining (Fig. 3 4 . The total results of the immunohistochemical analyses are compared with those from PCR studies for individual tumors in Table IV . The results for CEA expression at the mRNA and the antigen level correlate well in 17 from 19 ovarian tumors analyzed. For NCA-50/90, the tumors positive at the mRNA level were also positive at the antigen level. However, NCA-50/90 and NCA-95 antigen were found in 5/19 and 4/19 tumors, respectively, that were apparently negative for the corresponding transcripts. In all those cases, these NCA species were located focally in only a few tumor cells (< 5% total tumor cells) and/or were present within granulocytes (Fig. 3c) in areas of inflammation or in non-identifiable cells.
The number of granulocytes or non-identifiable cells stained was often equal to or greater than the number of positive tumor cells.
DISCUSSION
Using a computer program specifically written for this purpose (Lucas et al., 1991) , we have synthesized and tested oligonucleotide primer sets against individual CEA-related cDNA clones that specifically amplify CEA, NCA, CGM6 (NCA-95), BGP, CGM1, CGM7 transcripts and a set that will amplify only members of the PSG sub-group. For other members of the CEA-gene family (CGM2, CGMS, 9, 10 and l l ) , no transcripts have so far been described. Furthermore, sequence analyses indicate that these members, apart from CGM2, contain stop codons and apparently represent pseudogenes (Khan et al., 1992) . In future, the possibility of analyzing the expression of different splice products from individual genes, e.g., BGP or individual PSGs (Thompson et al., 1991) , may also be taken into consideration in the design of new oligonucleotide primers. Furthermore, we are presently developing a CGM2-specific primer set in the search for transcripts from this gene.
The results gained in the analysis of selected tumors located in the brain revealed no CEA-related transcripts in neuroepithelial tumors nor in mesenchymal tumors. On the other hand, a poorly differentiated adenocarcinoma, which represents a primary nasal-sinus tumor, was shown to co-express CEA and NCA transcripts. These data support immunohistochemical studies carried out by Ang et al. (1990) , who were unable to find CEA in 19 different brain primary tumors, whereas 6 brain metastases of primary tumors in the gastrointestinal tract were positive. Our results indicate that the sensitivity level of the RT/PCR is acceptable, in that the expected positivity and negativity based on published immunohistochemical data is reproduced.
Co-expression of NCA and CEA transcripts in ovarian mucinous adenocarcinomas was confirmed using MAbs specific against CEA and NCA-50/90. Other immunohistochemical investigations into the expression of CEA and NCA in ovarian tumors correlate well with our data (Motoyama et al., 1990) . In brief, these investigations also identified CEA and NCA in all ovarian mucinous tumors. CEA and NCA were also present in a few endometrioid and clear-cell carcinomas, but rarely in serous ovarian carcinomas, although only a small percentage of tumor cells were positive. Co-expression of CEA and NCA is often found in other types of adenocarcinomas, eg., colonic adenocarcinomas, as shown by DNA/RNA hybridization analyses (Chi et al., 1991) . The immunohistochemical staining on serial sections has often, but not always, revealed that the same tumor cells express both CEA and NCA. It appears that co-regulation of gene expression may exist in such cases. The genes encoding CEA and NCA are directly adjacent on the long arm of chromosome 19, being separated by only approximately 16 kb (data not shown). The coordination of expression of these genes could, therefore, be under the control of common cis-acting regulatory elements. However, in granulocytes, NCA but not CEA is expressed (Berling et al., 1990) , indicating that gene-specific control elements must also exist. Indeed, in these investigations, some of the tumor cells expressed CEA but not NCA, or vice versa. In a few other tumors, the CEAall primer set yielded amplification products, but the specific primer sets were all negative (Table 111 ). This suggests either amplification of unknown CEA-gene-family members, or more probably, co-expression of more than one known family member at low levels where individual transcripts cannot be visualized at the present sensitivity level. However, confirmation of such low expression levels would be only of academic interest.
With 200 ng of total RNA, the sensitivity of the PCR system was lower than that of the immunohistochemical method, since in the serous, clear-cell and endometrioid ovarian carcinomas, as well as one mucinous carcinoma, no CEA-related transcripts were detected, The PCR conditions were then modified by increasing the amount of total RNA to 1 pg. Under these conditions, the immunochemical and PCR analyses yielded more comparable results for expression of CEA-gene-family members. However, the focal staining seen in some tumor cells for NCA-50/90 and NCA-95 was still not detected with the PCR system. Although the PCR sensitivity may easily be further increased, problems could then arise with amplification of NCA, CGM1, CGM6, CGM7 and BGP transcripts present in granulocytes/leukocytes (Berlinget al., 1990; Kuroki et al., 1991) that would lead to false positives. Indeed, the where NCA transcripts were found, immunohistochemical analysis confirmed that the tumor cells themselves were NCA-50/90-positive. Even without the latter control, where NCA products are found in the absence of amplification products for CGM6, as in all the tumors investigated here, it may be concluded that NCA is, indeed, expressed in the tumor cells and not in granulocytes, since steady-state CGM6 mRNA levels are generally higher than NCA mRNA levels in granulocytes (Berling et aL, 1990) .
In general, this RT/PCR assay provides a useful system for specific identification of transcripts for each CEA-related gene. This cannot be achieved at the antigen level for all family members, due to the lack of specific antibodies for each species, or through DNA/RNA hybridization studies, because many probes will cross-hybridize or be of limited sensitivity. A further advantage of this PCR system is that its unlimited sensitivity makes it feasible to carry out such studies on biopsy material (e.g., fine-needle aspirates) where the amounts of tumor tissue available for analysis are very small. In such cases, higher sensitivity may be attained by increasing the number of cycles rather than the R N A amounts, which will also be limiting.
The preliminary studies presented here indicate that not only CEA, but also NCA, may be a useful tumor marker for ovarian mucinous adenocarcinomas, whereas the expression of other CEA-family members is more limited or completely absent from the tumors investigated so far. These analyses will be continued and further optimized on other tumors in which expression of CEA and CEA-related antigens have been reported, eg., tumors of the breast, lung and pancreas, and trophoblastic tumors.
